RobertASandhausMDPhD

Pulmonology • Denver, CO

Asthma & COPD, Critical Care Medicine

Professor of Medicine

Join to view full profile

Dr. Sandhaus is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sandhaus' full profile

Already have an account?

Office
1400 Jackson St
Denver, CO 80206
Phone+1 303-388-4461

Fax+1 303-270-2206

Summary

Dr. Robert Sandhaus is a pulmonologist in Denver, CO. He received his MD and PhD from Stony Brook University School of Medicine with residency at Beth Israel Hospital in Boston and fellowship at UCSF. He has been in practice 41 years. He specializes in pulmonary medicine and is experienced in chronic obstructive pulmonary disease, critical care medicine, and alpha-1 antitrypsin deficiency.

Education & Training

University of California (San Francisco)Fellowship, Pulmonary Disease and Critical Care Medicine, 1978 - 1981
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1976 - 1978
Beth Israel Deaconess Medical CenterFellowship, Internal Medicine, 1976 - 1978
Stony Brook UniversityPh.D, Experimental Pathology/Cell Biology, 1971 - 1976
Stony Brook University Health Sciences Center School of MedicineClass of 1976
Haverford CollegeB.A, Molecular Biology, 1967 - 1971

Certifications & Licensure

FL State Medical License 2000 - 2026
CO State Medical License 1981 - 2025
CA State Medical License 1978 - 1982
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

Clinical Investigator Award Grant NHLBI, National Institutes of Health, 1980-1985
Member Alpha Omega Alpha, 1976
Award for meritorious research American College of Pathology-Sheard Sanford- Bausch & Lomb, 1975

Clinical Trials

Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency Start of enrollment: 2007 Mar 01
Completed
Phase 2, Phase 3
Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency Start of enrollment: 2010 Jun 01
Completed
Phase 2
Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD) Start of enrollment: 2008 Jan 01
Completed
Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency Start of enrollment: 2015 Dec 01
Active, not recruiting
Join now to see all

Publications & Presentations

PubMed

Physical and mental health trajectories: A longitudinal SF-36 analysis in Alpha-1 antitrypsin deficiency-associated COPD.
Radmila Choate, Kristen E Holm, Robert A Sandhaus, David M Mannino, Charlie Strange
Respiratory Medicine. 2024-10-14
Analysis of alpha-1-antitrypsin (AAT)-regulated, glucocorticoid receptor-dependent genes in macrophages reveals a novel host defense function of AAT.
Xiyuan Bai, Junfeng Gao, Xiaoyu Guan, Drew E Narum, Lorelenn B Fornis
Physiological Reports. 2024-07-01
Clinical trial attitudes among individuals with Alpha-1 antitrypsin deficiency.
Kristen E Holm, Robert A Sandhaus, Sheri Allison, Charlie Strange
Respiratory Medicine. 2024-05-23

Journal Articles

Comorbidity Associations with AATD Among Commercially Insured and Medicare Beneficiaries with COPD in the US
Robert Sandhaus, MD, Dove Press
Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin.
Sandhaus RA, Am J Respir Crit Care Med 158:49-59
A combined pulmonary-radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation.
Barr RG, Berkowitz EA, Bigazzi F, Bode F, Bon J, Bowler RP, Chiles C, Crapo JD, Criner GJ, Curtis JL, Dass C, Dirksen A, Dransfield MT, Edula G, Erikkson L, Friedland..., COPD 9:151-159
Alpha-1 Antitrypsin Deficiency: Which Test? When?
Nagabhushanam V, Harbeck RJ, Sandhaus RA, Clinical Chemistry 50:15-29
Development of Predictive Models for Airflow Obstruction in Alpha-1-Antitrypsin Deficiency.
Castaldi PJ, Demeo DL, Kent DM, Campbell EJ, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard SI, Stocks JM Stoller JK, Strange C, Turino G, Sandhaus RA, Griffit..., Am J Epidemiol. 170:1005-1013
Heritability of lung function in severe alpha-1 antitrypsin deficiency.
Demeo DL, Campbell EJ, Brantly ML, Barker AF, Eden E, McElvaney NG, Rennard SI, Stocks JM, Stoller JK, Strange C, Turino G, Sandhaus RA, Silverman EK, Hum Hered 67:38-45
Alpha-1 antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary note.
Sandhaus RA, Turino G, Stocks J, Strange C, Trapnell BC, Silverman EK, Everett SE, Stoller JK, Chest 134:831-834
Determinants of airflow obstruction in severe alpha-1 antitrypsin deficiency.
DeMeo DL, Sandhaus RA, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard S, Burchard E, Stocks JM, Stoller JK, Strange C, Turino GM, Campbell EJ, Silverman EK, Thorax 62:806-813
Risk factors for symptom onset in PI*Z alpha-1 antitrypsin deficiency.
Mayer AS, Stoller JK, Bucher Bartelson B, Sandhaus RA, Newman LS, International J COPD 1:485–492
Multi-center study: The biochemical efficacy, safety and tolerability of a new α1-proteinase inhibitor, Zemaira.
Stocks JM, Brantly M, Pollock D, Barker A, Kueppers F, Strange C, Donohue JF, Sandhaus R, J COPD 3:17-23
Results of a survey of patients with alpha-1 antitrypsin deficiency.
Strange C, Stoller JK, Sandhaus RA, Dickson R, Turino G, Respiration 73:185-190
α1-Antitrypsin deficiency -- 6: New and emerging treatments for α1-antitrypsin deficiency.
Sandhaus RA, Thorax 59:904-909
Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events.
Stoller JK, Fallat R, Schluchter MD, O'Brien RG, Connor JT, Gross N, O'Neil K, Sandhaus RA, Crystal RG, Chest 123:1425-34
Alpha1-antitrypsin deficiency therapy: pieces of the puzzle.
Sandhaus RA, Chest 119:676-678
Occupational exposure risks in individuals with PI*Z alpha1-antitrypsin deficiency.
Mayer AS, Stoller JK, Bucher Bartelson B, Ruttenber AJ, Sandhaus RA, Newman LS, Am J Respir Crit Care Med 162:553-588
Further studies of human alveolar macrophage alanine-p-nitrophenyl esterase.
Rosenberg R, Sandhaus R, and Janoff A, Am Rev Respir Dis 106:114-115
The New England Journal of Medicine: CD Product Review.
Sandhaus RA, CD-ROM World 8:74-76
Bacterial lipopolysaccharide enhances chemoattractant-induced elastase secretion by human neutrophils.
Fittschen C, Sandhaus RS, Worthen GS, Henson PM, J Leukoc Biol 43:547-556
O2 metabolites and neutrophil elastase synergistically cause edematous injury in isolated rat lungs.
Beard BR, Cheronis JC, Sandhaus RA, Berger EM, White CW, Repine JE, J Appl Physiol 61:2224-2229
Epithelial permeability produced by phagocytosing neutrophils in vitro.
Sugahara K, Cott GR, Parsons PE, Mason RJ, Sandhaus RA, Henson PM, Am Rev Respir Dis 133:875-881
Neutrophil-mediated injury to endothelial cells. Enhancement by endotoxin and essential role of neutrophil elastase.
Smedley LA, Tonnesen MG, Sandhaus RA, Haslett C, Guthrie LA, Johnston RB,Jr, Henson PM, Worthen GS, J Clin Invest 77:1233-1243
Genetic basis of chronic obstructive pulmonary disease.
Sandhaus RA, Seminars in Respiratory Medicine 7:353-357
Modems and the M.D: The microcomputer as a communications tool.
Sandhaus RA, Chest 87:4-5
From wheezes to lymphocytes via the esophageal balloon.
Downey GP, Sandhaus RA, Irvin CG, Respir Care 30:52-55
Elastolytic proteinases of the human macrophage.
Sandhaus RA, MacCarthy K, Musson R, Henson P, Chest 83s:60-62
Join now to see all

Books/Book Chapters

Second International Symposium on Pulmonary Emphysema and Proteolysis.
Chapter: Elastase may play a central role in the migration of neutrophils through connective tissue
Sandhaus RAEditors: Charles Mittman.Academic Press, New York
Proteases and Biological Control.
Chapter: Human neutrophil elastase: in vitro effects on natural substrates suggest important physiological and pathological actions
Page 603 - 620Janoff A, Blondin J, Sandhaus RA, Mosser A, and Malemud CEditors: Reich E, Rifkin D, and Shaw E.Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
Drugs for the Respiratory System
Chapter: Newer agents
Page 227 - 236Sandhaus RAEditors: Cherniack RM.Grune & Stratton, Inc., Orlando, FL
Current Therapy of Respiratory Disease -2.
Chapter: Alpha1-proteinase inhibitor deficiency
Page 125 - 126Sandhaus RAEditors: Cherniack RM.B.C. Decker, Inc, Philadelphia, PA
Essentials of Internal Medicine in Clinical Podiatry.
Chapter: Pulmonary medicine
Sandhaus RAW.B. Saunders, Philadelphia, PA
Proteases, Protease Inhibitors and Protease-Derived Peptides.
Chapter: Alpha1-Antitrypsin Augmentation Therapy
Page 97 - 102Sandhaus RAEditors: Cheronis JC and Repine JE.Birkhauser Verlag, Basel, Switzerland
Long-Circulating Liposomes: Old Drugs, New Therapeutics.
Chapter: Clinical and preclinical studies with low-clearance liposomal amikacin
Page 213 - 225Fielding RM, Mukwaya G, Sandhaus RAEditors: Woodle MD and Storm G.Landes Bioscience, Austin, TX
Pediatric Respiratory Medicine.
Chapter: α1-Antitrypsin Deficiency
Page 1015 - 1024Sandhaus RAEditors: Taussig LM and Landau LI.Mosby Elsevier, Philadelphia, PAEdition 2,
Alpha-1 Disease Management and Prevention Program: The Big Fat Reference Guide to Alpha-1.
Robert A. SandhausAlphaNet Press
Join now to see all

Lectures

Retention, localization, and fate of endotracheally administered protease in an animal model of pulmonary emphysema.
Stony Brook, New York

Press Mentions

Non-Tuberculous Mycobacterial Lung Disease Due to Multiple “Minor” Risk Factors: An Illustrative Case and a Review of These “Lesser Elements”November 6th, 2020
Non-Tuberculous Mycobacterial Lung Disease Due to Multiple “Minor” Risk Factors: An Illustrative Case and a Review of These “Lesser Elements”September 5th, 2020
Does COPD Have a Genetic Component?June 2nd, 2017
Join now to see all